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Beta-blockers in patients with cirrhosis and infections: don’t blame too soon!
To the Editor:
We thank Drs Schiavon Narciso-Schiavon for their
interest in our study, allowing us to better clarify some
of our findings (1). We performed a cross-sectional
study in a large prospectively cohort of hospitalized
cirrhotics. The primary aim was to identify the possi-
ble correlation between medications, widely prescribed
in cirrhotics, and infections. We found that PPI-users
had a higher rate and BBs-users a lower rate of infec-
tions. The lower infection rate and better prognosis of
BB-users can not be attributed, as suggested by Schi-
avon et al., to a higher proportion of variceal bleeding
in this group; in fact, the large majority of patients
hospitalized for bleeding were excluded from the study
as they came to our ward already on systemic antibi-
otic treatment (which is usually started in the emer-
gency room) and this would have represented a
confounding factor. Only few patients with variceal
bleeding were included: they developed bleeding after
enrolment and were equally distributed between those
taking and not taking BBs.
Following the recent debate about the ‘therapeutic
window’ of BBs in cirrhotic patients (2–4), we were
also interested in evaluating possible harmful effects of
BBs in cirrhotic patients with infections. This was a
secondary aim of our study and we certainly recognize
that the study was underpowered for this purpose.
From our series, 140 patients had an infection; of
them 37 were BB-users and 103 not-users. Unexpect-
edly, patients on BBs showed a trend towards a lower
incidence of sepsis (40 vs 57%), septic shock (8 vs
15%), hepatorenal syndrome (14 vs 17%) and mortal-
ity (15 vs 40%) vs not-users. Because of the limited
sample size, these differences were not statistically sig-
nificant; however, we believed that these data could be
of interest also to promote larger studies. Furthermore,
questioning the hypothesis of an impairment of the
haemodynamic response by BBs during acute events,
these patients were able to increase the heart rate dur-
ing the septic episode, though to a lesser degree than
those not on BBs. If our results are confirmed, this
will be argued against the suggestion to suspend BBs
in patients with infections (5).
In conclusion, our study indicates that BBs are asso-
ciated with a lower rate of bacterial infections in
patients with cirrhosis. Moreover, we showed a trend
towards a beneficial effect of BBs in patients with
cirrhosis who develop infections.
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